The FDA has approved Tibotec Pharmaceuticals' Prezista for treatment-resistant HIV patients. "One of the greatest challenges in HIV care is finding therapies for treatment-experienced patients," said Michael S. Saag, M.D., director of the AIDS Outpatient Clinic and the University of Alabama at Birmingham Center for AIDS Research. "This is an important new option for the thousands of people with HIV in the United States who are resistant to more than one protease inhibitor." Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.